Mr. Kleu has devoted his entire career to building commercial teams and developing strategies for various companies within the pharmaceutical industry. Prior to SNP Therapeutics, Mr. Kleu began his career with the Upjohn Company (Pfizer) where he worked in various commercial leadership roles before joining Daiichi Sankyo as an inaugural member of the management team charged with building its’ first U.S. commercial presence. Mr. Kleu served as Vice President of Sales for Daiichi Sankyo, (a global pharmaceutical company; top 20 worldwide). Mr. Kleu was a member of the executive management team that built the US Commercial division to over 3,000 employees and $3B in annual US revenue through the launch of 6 successful brands in 15 years. Over the past 5 years Mr. Kleu has worked as a Vice President for the commercial division of Syneos Health (Nasdaq:SYNH), a fully integrated biopharmaceutical solutions provider, specializing in Contract Research  and Contract Commercial solutions for the pharma sector). He has partnered with a number of major companies to build and execute commercial strategies for many successful brands (i.e., J&J, Pfizer, Eli Lilly, and Forest Labs). While at Syneos Health Mr. Kleu has also been successful in building commercial strategies for new start-up companies by providing a variety of services from his teams to clients, (i.e., consulting, marketing, operations, compliance, legal, compensation, medical, payer reimbursement, recruiting, and training). Mr. Kleu is a graduate of The University of North Carolina at Greensboro with a major in Business Administration and a concentration in Marketing. Jon and his family reside in the Raleigh, North Carolina area.

Steven Zeisel, MD, PhD is the Director of the University of North Carolina's Nutrition Research Institute, a world-renowned scientist and a Kenan Distinguished University Professor in Nutrition and Pediatrics. Dr. Zeisel is internationally recognized for his research in nutrigenetics and nutrient requirements. Dr. Zeisel is the Kenan Distinguished University Professor in the Department of Nutrition in the Gillings School of Global Public Health and School of Medicine at the University of North Carolina at Chapel Hill. Dr. Zeisel earned his MD from Harvard Medical School in 1975, was a resident in pediatrics at Yale University from 1975–1977, and earned his PhD in nutrition at the Massachusetts Institute of Technology in 1980. He served as chair of the Department of Nutrition at UNC from 1990-2005. Dr. Zeisel is the Director of the UNC Nutrition Research Institute and Director of the UNC Nutrition and Obesity Research Center (one of 12 centers of excellence funded by the US National Institutes of Health). Dr. Zeisel serves on the Federation of American Societies for Experimental Biology (FASEB) Journal editorial board. His research team focuses on the essential nutrient choline and why there are individual differences in nutrient metabolism, using new approaches in nutrigenetics and metabolomics. Dr. Zeisel has proven that humans require choline and that this nutrient is critical for normal brain development, and for liver and muscle function. Based on his research, the US Institute of Medicine set a dietary requirement for choline in 1998. Currently, Zeisel’s team is investigating how gene misspellings alter dietary requirements, how diet can add marks to genes which turn them on an off (epigenetics), and how choline is needed for normal liver, muscle and sperm function. All of these studies have been supported by grants from the US National Institutes of Health. Dr. Zeisel has authored more than 350 scientific publications and has won numerous awards including the prestigious National Institute of Environmental Health Sciences’ Falk Award, the American Society for Nutrition’s Osborne and Mendel Award, the American College of Nutrition’s Award  

Jamie Platt is an experienced and recognized leader in clinical genomics and molecular diagnostics. After completing a PhD in Molecular Biology and fellowship as a Post-Doctoral Scholar at UC Berkeley, Jamie focused her academic and research interests toward innovation and application in clinical diagnostics. Jamie spent nearly 15 years at Quest Diagnostics, overseeing both Operational and R&D functions, beginning with Infectious Disease and ultimately initiating and overseeing Quest’s Advanced Sequencing (Genomics) program spanning Genetics, Oncology, Immunology, Infectious Disease, and Neurology. Jamie and her team developed and validated the first commercially available NGS-based diagnostic in 2006, helping to transform NGS technology from an influential research tool to a viable and powerful clinical platform. Jamie ultimately oversaw the entire Advanced Sequencing (NGS) portfolio for all of Quest Diagnostics and continued to grow the genomics business both organically and through acquisition (e.g., Athena Diagnostics and Celera). Leading the translation of NGS technology from research into clinical diagnostics, also allowed her to develop an extensive professional network collaborating on projects with high-profile key opinion leaders like George Church, Eric Topol, and Francis Collins (Director of The NIH). Jamie’s early experience in clinical NGS also led her to contribute to professional guidelines in NGS, such as CLSI MM09, NYS NGS Guidelines for Somatic Variant Detection, NIST Genomes In-A-Bottle, and the FNIH QCM Project for ctDNA (circulating tumor DNA). 

After leaving Quest Diagnostics, Jamie focused on helping laboratories, pharmaceutical companies, and platform (instrument) providers bridge gaps in their knowledge of genomics applications and the market landscape. Jamie has helped more than 25 laboratories achieve CLIA licensure, in addition to gaining CAP accreditation (7 laboratories), ISO 15189 & ISO 14385 certification (5 entities), NYS CLEP (2 laboratories) CE Mark (3 products), FDA Breakthrough Device Designation (2 products), and Local Coverage Determination (LCD) for CMS via Palmetto MolDx. Jamie has supported several FDA PMA and 510K submissions by NGS platform providers (Illumina and ThermoFisher) through clinical and orthogonal studies. Jamie also serves as an NGS specialized auditor for CAP (The College of American Pathologists)and is a member of the C21 (Coalition for 21st Century Medicine) Regulatory Working Group. Jamie is frequently invited as a key-note speaker, podium presenter, and workshop instructor at research and professional conferences. Her recent experience in liquid biopsy and personalized medicine is a natural extension and evolution of a career committed to enabling significant clinical diagnostic insights through genomics.

Brian began his career in the 80’s as the General Accountant for a government contractor, where he automated the accounting departments’ processes saving hundreds of hours of overtime each year. From there, he enjoyed a broad range of positions including:  Registered Representative at Merrill Lynch, Trust Officer at Nations Bank, Retirement Consultant at William M. Mercer, Inc., CFO / FINOP for Triune Capital Advisors, and Supervisory Principal / Designated Principal for LPL Financial where he supervised fifty six advisors and nineteen field OSJ’s, performing supervisory office visits to ensure compliance. He has successfully guided both RIA’s and BD’s through FINRA, SEC and State of NC Audits, and has worked with over twenty start-ups.  Brian also holds Series 7, 9, 10, 24, 27, 63, 65, and 82 licenses.  

Brian enjoys running, travelling, and trout fishing. He currently serves as the Vice Chairman of the Board for Faith, Hope & Love – a Christian based, after school mentoring program.